Findings

What do systematic reviews say?

3 questions · 3 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 2 · 66.7%Low 1 · 33.3%Moderate 0 · 0%High 0 · 0%

Response rate · women with recurrent epithelial ovarian cancer

It is very uncertain whether 175 mg/m2 paclitaxel changes response rate compared with 250 mg/m2 paclitaxel (very low certainty).

1 finding from 1 review

Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer 2022 · Cochrane Headline outcomes only
RR 0.86 [0.4, 1.89]
1 study · 265 participants
Very low

Response rate ‐ platinum‐sensitive · women with recurrent epithelial ovarian cancer

175 mg/m2 paclitaxel may leads to lower response rate ‐ platinum‐sensitive compared with 250 mg/m2 paclitaxel (low certainty).

1 finding from 1 review

Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer 2022 · Cochrane Headline outcomes only
RR 0.6 [0.39, 0.93]
1 study · 213 participants
Low

Response rate ‐ platinum‐resistant · women with recurrent epithelial ovarian cancer

It is very uncertain whether 175 mg/m2 paclitaxel changes response rate ‐ platinum‐resistant compared with 250 mg/m2 paclitaxel (very low certainty).

1 finding from 1 review

Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer 2022 · Cochrane Headline outcomes only
RR 1.34 [0.7, 2.57]
1 study · 52 participants
Very low